Because of the toxicity of ROR1-targeted CAR-T cells attributable to ROR1 expression in normal tissues, CAR-T cells have been engineered with synthetic Notch receptors EpCAM and B7-H3 to improve selectivity, specificity, and tumor regression in ROR1-expressing tumor cells with less toxicity (55). Here, EPCAM is linked to neoplasm.